Loading institutional data...
Loading institutional data...
Held by 336 of 5,944 reporting institutions (95th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $114.86 today, the market must believe free cash flow compounds 26.4%/yr for a decade (off $155M normalized FCF).
The market's 26.4% is in line with its 9-yr track record.
2-stage DCF · 0.11B shares · net debt -$120M
mean 40.8% · volatility σ 81% · implied rate exceeded in 3/9 yrs
Central path = implied 26.4%/yr growth; shaded band = ±1σ (81%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| CORT | $12.2B | 140.1× | 262.3× | 16.0× | 12.8% | 98.3% | 13.1% | 15.4% | 15.4% | — | 336 |
Peers = companies sharing CORT's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $761.4M 100.0% | $675.0M 100.0% | $482.4M 100.0% | $401.9M 100.0% | $366.0M 100.0% | $353.9M 100.0% | $306.5M 100.0% | $251.2M 100.0% | $159.2M 100.0% | $81.3M 100.0% |
| Cost of Revenue | $13.0M 1.7% | $10.9M 1.6% | $6.5M 1.3% | $5.4M 1.3% | $5.3M 1.4% | $5.6M 1.6% | $5.5M 1.8% | $5.2M 2.1% | $3.6M 2.2% | $2.1M 2.5% |
| Cost of Products | — | — | — | — | — | — | — | — | $3.6M 2.2% | $2.1M 2.5% |
| Research & Development | $254.9M 33.5% | $246.9M 36.6% | $184.4M 38.2% | $131.0M 32.6% | $113.9M 31.1% | $114.8M 32.4% | $89.0M 29.0% | $75.2M 29.9% | $40.4M 25.4% | $23.8M 29.3% |
| Selling, General & Admin | $448.7M 58.9% | $280.3M 41.5% | $184.3M 38.2% | $152.8M 38.0% | $122.4M 33.4% | $105.3M 29.8% | $100.4M 32.7% | $81.3M 32.4% | $62.4M 39.2% | $45.2M 55.6% |
| Total Operating Expenses | $716.6M 94.1% | $538.1M 79.7% | $375.1M 77.8% | $289.2M 72.0% | $241.5M 66.0% | $225.7M 63.8% | $194.9M 63.6% | $161.8M 64.4% | $106.3M 66.8% | $71.1M 87.5% |
| Operating Income | $44.8M 5.9% | $137.0M 20.3% | $107.3M 22.2% | $112.6M 28.0% | $124.5M 34.0% | $128.2M 36.2% | $111.6M 36.4% | $89.5M 35.6% | $52.9M 33.2% | $10.2M 12.5% |
| Interest Expense | — | — | — | — | — | — | — | — | — | $2.0M 2.5% |
| Other Income (Expense), net | $21.7M 2.8% | $24.5M 3.6% | $17.3M 3.6% | $3.6M 0.9% | $529K 0.1% | — | — | — | — | — |
| Pretax Income | $66.5M 8.7% | $161.5M 23.9% | $124.6M 25.8% | $116.2M 28.9% | $125.0M 34.2% | $131.6M 37.2% | $116.7M 38.1% | $92.2M 36.7% | $52.8M 33.2% | $8.1M 10.0% |
| Income Tax Expense | -$33.2M -4.4% | $20.3M 3.0% | $18.4M 3.8% | $14.8M 3.7% | $12.5M 3.4% | $25.6M 7.2% | $22.5M 7.3% | $16.7M 6.7% | -$76.3M -47.9% | $0 0.0% |
| Net Income | $99.7M 13.1% | $141.2M 20.9% | $106.1M 22.0% | $101.4M 25.2% | $112.5M 30.7% | $106.0M 30.0% | $94.2M 30.7% | $75.4M 30.0% | $129.1M 81.1% | $8.1M 10.0% |
| Per Share | ||||||||||
| EPS (Basic) | $0.95 | $1.35 | $1.02 | $0.95 | $0.97 | $0.92 | $0.82 | $0.65 | $1.14 | $0.07 |
| EPS (Diluted) | $0.82 | $1.23 | $0.94 | $0.87 | $0.89 | $0.85 | $0.77 | $0.60 | $1.04 | $0.07 |
| Weighted Avg Shares (Basic) | 103.9M | 103.2M | 103.6M | 106.8M | 115.7M | 115.4M | 114.3M | 115.3M | 113.5M | 110.6M |
| Weighted Avg Shares (Diluted) | 120.0M | 113.5M | 111.7M | 116.0M | 126.0M | 124.2M | 122.6M | 126.7M | 124.5M | 116.1M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
4/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $173M buybacks = $173M returned on $142M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A cash-return story — far more went to shareholders than back into the business (mature, low-reinvestment).
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: 15%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $120M covers all $45M of scheduled principal — no refinancing pressure. Scheduled principal only (excludes interest & revolver draws). As of 2012-09-30 (10-Q).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Coverage is adequate but not comfortable. Effective rate ~13.9% on $15M of debt. Interest last disclosed in FY2016 (no longer broken out).
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
No material risks flagged.
Where each multiple sits in its own 14-yr range · 93th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Returns are margin-driven, not leverage-driven — higher quality.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 2.1 | 1.8 | 1.6 | 1.4 | 1.3 | 1.3 | 1.6 | 1.7 |
| R&D | 29.9 | 29.0 | 32.4 | 31.1 | 32.6 | 38.2 | 36.6 | 33.5 |
| SG&A | 32.4 | 32.7 | 29.8 | 33.4 | 38.0 | 38.2 | 41.5 | 58.9 |
| Operating Income | 35.6 | 36.4 | 36.2 | 34.0 | 28.0 | 22.2 | 20.3 | 5.9 |
| Income Tax | 6.7 | 7.3 | 7.2 | 3.4 | 3.7 | 3.8 | 3.0 | -4.4 |
| Net Income | 30.0 | 30.7 | 30.0 | 30.7 | 25.2 | 22.0 | 20.9 | 13.1 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on CORT: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.